Medical Imaging Agents Global Market – Forecast to 2028

Publishing Date : January, 2022
Report Code : HCPH0114
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic imaging investigation are known as medical imaging agents which comprise contrast agents and nuclear imaging agents, these agents are administered directly through veins, arteries, and joints or consumed orally. X-ray/computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney. Nuclear medicine is a highly multi-disciplined medical imaging specialty, where, SPECT and PET scanners are used along with small amounts of radioactive material in order to diagnose diseases. According to IQ4I estimates, the Medical imaging agents global market is expected to grow at mid single-digit CAGR from 2021 to 2028 to reach $12,881.0 million by 2028.

Medical imaging agents global market is segmented based on molecule/isotope, modality, application, route of administration, imaging and end-users. The market based on molecule/isotope segmented into contrast agents and nuclear imaging agents, where the contrast agents segment commanded the largest revenue in 2021 and the segment is expected to grow at  mid single-digit CAGR from 2021 to 2028. The contrast agents global market is further segmented based on molecule into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium and iron-based contrast agents. Iodine-based contrast agents market contributed the largest revenue in 2021 and is expected grow at low single-digit CAGR of 4.7% from 2021 to 2028 and the microbubble segment is growing rapidly at late teen double-digit CAGR from 2021 to 2028 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. The non-Ionic Iodine-based contrast agents market accounted for the largest share in 2021 and the market is projected to grow at a mid single-digit CAGR from 2021 to 2028. Because of lower osmolality, better tolerance and another advantage, non-ionic iodine contrast agents are preferred and they are less toxic. Ionic Iodine based contrasts are further segmented based on chemical structure into monomers and dimers. Monomers accounted for the largest share in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. Non-Ionic as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and help in reducing the neurotoxicity. The gadolinium contrast agents are further segmented based on chemical structures into macrocyclic and linear agents, among which the macrocyclic commanded the largest share in 2021 and is expected to grow at high single-digit CAGR from 2021 to 2028. Macrocyclic agents are further segmented into ionic and non-ionic agents, among which, non-ionic commanded the largest revenue in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. The Ionic segment is expected to grow at a high single-digit CAGR from 2021 to 2028.

As estimated by IQ4I Research, the nuclear imaging agents global market is poised to grow at mid single-digit CAGR from 2021 to 2028. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) is boosting nuclear imaging agent's market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear imaging agents market.

The nuclear imaging agents global market based on isotopes are segmented into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xe-133, Rhenium (Re-186), Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Technetium (Tc-99m) isotope commanded the largest revenue in 2021 and is expected to grow at mid single-digit  CAGR from 2021 to 2028 and Gallium (Ga-68) is projected to grow at high double-digit CAGR from 2021 to 2028 due to its increasing use in the diagnosis of neuroendocrine tumors and emerging use in prostate cancer.

The Medical imaging agents market based on modality is segmented into X-ray/CT, MRI, Ultrasound, SPECT and PET. X-Ray/CT market held the largest market revenue in 2021 and is expected to grow at low single-digit CAGR from 2021 to 2028 and the ultrasound segment is growing rapidly at late teen double digit CAGR from 2021 to 2028 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The Medical imaging agents market based on applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, pulmonary, hepatology and others which include neck, bone and salivary gland imaging. The cardiovascular market accounted for the largest share in 2021 and is expected grow at mid single-digit CAGR from 2021 to 2028 and cancer is the fastest-growing segment with a high single-digit CAGR from 2021 to 2028 due to an increase in cancer imaging such as lung, thyroid and breast cancer imaging procedures using Iodine, Gadolinium and microbubble contrast agents and radiopharmaceuticals.

Medical imaging agents market by route of administration is segmented into intravascular, oral, rectal and others, which include intraosseous, intrathecal and intravesical. Intravascular accounted for the largest share in 2021 and is the fastest-growing market with a projected mid single-digit CAGR from 2021 to 2028 due to an increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium, microbubble contrast agent and nuclear imaging agents to be administered intravascular.

The medical imaging agents market based on imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging commanded the largest revenue in 2021 and is expected grow mid single-digit CAGR from 2021 to 2028. The interventional imaging segment is estimated to grow at early teens CAGR from 2021 to 2028 due to an increase in image guide procedures and an increase in the aging population who usually opt for minimally invasive procedures.

Medical imaging based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2021, and the market is expected to grow at mid single-digit CAGR from 2021 to 2028, the rising demand for the diagnosis using CT or X-Ray, MRI, ultrasound, SPECT and PET imaging procedures due to increase in incidence and prevalence of diseases, the ready availability of cyclotrons for the generation of isotopes and presence of trained technicians who can handle radioisotopes. The diagnostic & Ambulatory surgical centers segment is the fastest-growing market and is estimated to grow at high single-digit CAGR from 2021 to 2028 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW regions where the North America region commanded the largest revenue in 2021 and is expected to grow at mid single-digit CAGR from 2021 to 2028. Technological advancement in equipment increased utilization of fusion imaging and increase in incidence and prevalence of disease conditions requiring the use of diagnostic imaging have led the market growth in this region. However, the Asia-Pacific region is the fastest-growing market and is expected to grow at high single-digit CAGR from 2021 to 2028, due to increased healthcare awareness, improved economic growth, a large patient pool, and a rising aged population.

The Medical imaging agents global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the Medical imaging agents global market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Bracco Group (Italy), Curium Pharma (France), Cardinal Health (U.S), Lantheus Medical Imaging (U.S.), Sumitomo Chemicals (Japan), Novartis International AG (Advanced accelerator) (Switzerland), Fujifilm Holding Corporation (Japan), Fujipharma Co. Ltd (Japan), Jubilant Life science (India) and Beijing Beilu (China).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
        • 2.6.7.1     PROCEDURAL VOLUME ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING DEMAND FOR IMAGING AGENT-ASSISTED DIAGNOSTIC PROCEDURES
        • 3.3.1.2     PRODUCTION OF RADIOPHARMACEUTICALS FROM CYCLOTRONS
        • 3.3.1.3     THE GROWTH OF MEDICAL IMAGING TECHNOLOGIES IN EMERGING MARKETS
        • 3.3.1.4     USAGE OF HYBRID IMAGING
        • 3.3.1.5     INCREASING GERIATRIC POPULATION SUFFERING FROM CHRONIC DISEASE
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECTS ASSOCIATED WITH MEDICAL IMAGING AGENTS
        • 3.3.2.2     THE SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
        • 3.3.2.3     SHORTAGE OF RADIOLOGIST AND QUALIFIED TECHNICIANS
        • 3.3.2.4     HIGH COST AND SUPPLY SHORTAGE OF ISOTOPES
        • 3.3.2.5     UNCERTAINTY DUE TO FALL OUT OF GENUS CASE WHICH COULD LEAD TO THE RECLASSIFICATION OF IMAGING AGENTS AS MEDICAL DEVICES RESULTING IN ADDITIONAL EXPENSES FOR THE COMPANIES.
    • 3.4     REGULATORY GUIDELINES
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     JAPAN
      • 3.4.5     INDIA
      • 3.4.6     SOUTH KOREA
    • 3.5     REIMBURSEMENT TABLE
    • 3.6     CLINICAL TRIALS
    • 3.7     SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
      • 3.7.1     REACTORS/IRRADIATORS
      • 3.7.2     PROCESSING FACILITY
      • 3.7.3     GENERATORS
      • 3.7.4     HOSPITALS AND CENTRAL RADIO PHARMACIES
      • 3.7.5     CYCLOTRON
      • 3.7.6     LINAC BASED TC-99M PRODUCTION METHOD
    • 3.8     SUPPLY CHAIN ANALYSIS OF CONTRAST AGENTS
    • 3.9     LIST OF FDA APPROVED RADIOPHARMACEUTICALS
    • 3.10     PORTER’S FIVE FORCE ANALYSIS
      • 3.10.1     THREAT OF NEW ENTRANTS
      • 3.10.2     THREAT OF SUBSTITUTES
      • 3.10.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.10.4     BARGAINING POWER OF SUPPLIERS
      • 3.10.5     BARGAINING POWER OF BUYERS
    • 3.11     TECHNOLOGICAL ADVANCEMENTS
      • 3.11.1     ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY
      • 3.11.2     ADVANCEMENTS IN MRI CONTRAST AGENTS
      • 3.11.3     APPLICATION OF AI IN CONTRAST IMAGING
      • 3.11.4     XENON MAGNETIC RESONANCE IMAGING
      • 3.11.5     LINAC BASED TC-99M PRODUCTION
    • 3.12     MARKET SHARE ANALYSIS
      • 3.12.1     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.2     MARKET SHARE ANALYSIS OF MRI
      • 3.12.3     MARKET SHARE ANALYSIS OF X-RAY/CT
      • 3.12.4     MARKET SHARE ANALYSIS OF ULTRASOUND AGENTS
      • 3.12.5     MARKET SHARE ANALYSIS OF SPECT AGENTS
      • 3.12.6     MARKET SHARE ANALYSIS OF PET AGENTS
    • 3.13     MEDICAL IMAGING AGENTS MARKET – NUMBER OF SCANS, VOLUME OF IMAGING AGENTS CONSUMED, AND MARKET SIZE
      • 3.13.1     GLOBAL X-RAY/COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.13.2     NORTH AMERICA COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.13.3     EUROPE COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.13.4     APAC COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.13.5     ROW COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
    • 3.14     MAGNETIC RESONANCE IMAGING MARKET - PROCEDURE VOLUME, VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE
      • 3.14.1     GLOBAL MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.14.2     NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.14.3     EUROPE MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.14.4     APAC MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.14.5     ROW MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
    • 3.15     MEDICAL IMAGING AGENTS-FUNDING SCENARIO
    • 3.16     MEDICAL IMAGING AGENTS– DEALS AND APPROVALS
    • 3.17     SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
  • 4     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MOLECULE/ISOTOPE
    • 4.1     INTRODUCTION
    • 4.2     CONTRAST AGENTS
      • 4.2.1     IODINATED CONTRAST AGENTS
        • 4.2.1.1     IODINATED IONIC CONTRAST AGENTS
        • 4.2.1.2     IODINATED NON-IONIC CONTRAST AGENTS
          • 4.2.1.2.1     MONOMER
          • 4.2.1.2.2     DIMER
      • 4.2.2     GADOLINIUM-BASED CONTRAST AGENTS
        • 4.2.2.1     MACROCYCLIC CONTRAST AGENTS
          • 4.2.2.1.1     MACROCYCLIC IONIC CONTRAST AGENTS
          • 4.2.2.1.2     MACROCYCLIC NON-IONIC CONTRAST AGENTS
        • 4.2.2.2     LINEAR GADOLINIUM-BASED CONTRAST AGENTS
          • 4.2.2.2.1     LINEAR IONIC CONTRAST AGENTS
          • 4.2.2.2.2     LINEAR NON-IONIC CONTRAST AGENTS
      • 4.2.3     MICROBUBBLE CONTRAST AGENTS
      • 4.2.4     OTHERS CONTRAST AGENTS
    • 4.3     NUCLEAR IMAGING AGENTS
      • 4.3.1     TECHNETIUM (TC-99M)
      • 4.3.2     THALLIUM (TL-201)
      • 4.3.3     GALLIUM (GA-67)
      • 4.3.4     IODINE (I-123)
        • 4.3.4.1     SUPPLY CHAIN ANALYSIS OF IODINE-123 (I-123)
      • 4.3.5     XENON (XE-133)
      • 4.3.6     RHENIUM (RE-186)
      • 4.3.7     FLUORODEOXYGLUCOSE (18F-FDG)
        • 4.3.7.1     SUPPLY CHAIN ANALYSIS OF FLUORINE-18 (F-18)
      • 4.3.8     GALLIUM (GA-68)
        • 4.3.8.1     SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (GA-68)
        • 4.3.8.2     CHARACTERISTICS OF CURRENT GE-68/GA-68 GENERATORS
      • 4.3.9     RUBIDIUM (RB-82)
        • 4.3.9.1     PRODUCTION ANALYSIS OF STRONTIUM (SR-82)/ RUBIDIUM (RB-82)
      • 4.3.10     OTHERS
  • 5     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MODALITY
    • 5.1     INTRODUCTION
    • 5.2     X-RAY/COMPUTED TOMOGRAPHY (CT)
    • 5.3     MAGNETIC RESONANCE IMAGING (MRI)
    • 5.4     ULTRASOUND
    • 5.5     SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)
    • 5.6     POSITRON EMISSION TOMOGRAPHY (PET)
  • 6     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     CARDIOVASCULAR
    • 6.3     CANCER
    • 6.4     GASTROINTESTINAL
    • 6.5     MUSCULOSKELETAL
    • 6.6     NEUROLOGY
    • 6.7     NEPHROLOGY
    • 6.8     OBSTETRICS AND GYNECOLOGY
    • 6.9     PULMONARY
    • 6.10     HEPATOLOGY
    • 6.11     OTHERS
  • 7     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON ROUTE OF ADMINISTRATION
    • 7.1     INTRODUCTION
    • 7.2     INTRAVASCULAR
    • 7.3     ORAL
    • 7.4     RECTAL
    • 7.5     OTHERS
  • 8     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON IMAGING
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC IMAGING
    • 8.3     INTERVENTIONAL IMAGING
  • 9     MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON END-USERS
    • 9.1     INTRODUCTION
    • 9.2     HOSPITAL
    • 9.3     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
    • 9.4     OTHER END-USER
  • 10     REGIONAL ANALYSIS
    • 10.1     INTRODUCTION
    • 10.2     NORTH AMERICA
      • 10.2.1     THE U.S.
      • 10.2.2     REST OF N.A.
    • 10.3     EUROPE
      • 10.3.1     GERMANY
      • 10.3.2     FRANCE
      • 10.3.3     ITALY
      • 10.3.4     REST OF EUROPE
    • 10.4     ASIA-PACIFIC
      • 10.4.1     CHINA
      • 10.4.2     JAPAN
      • 10.4.3     SOUTH KOREA
      • 10.4.4     REST OF APAC
    • 10.5     REST OF THE WORLD
      • 10.5.1     TURKEY
      • 10.5.2     BRAZIL
      • 10.5.3     OTHERS
  • 11     COMPETITIVE LANDSCAPE
    • 11.1     INTRODUCTION
    • 11.2     APPROVALS
    • 11.3     ACQUISITIONS
    • 11.4     AGREEMENTS
    • 11.5     PARTNERSHIPS
    • 11.6     EXPANSION
    • 11.7     OTHERS
  • 12     MAJOR PLAYERS PROFILE
    • 12.1     BAYER GROUP
      • 12.1.1     OVERVIEW
      • 12.1.2     FINANCIALS
      • 12.1.3     PRODUCT PORTFOLIO
      • 12.1.4     KEY DEVELOPMENTS
      • 12.1.5     BUSINESS STRATEGY
      • 12.1.6     SWOT ANALYSIS
    • 12.2     BRACCO GROUP
      • 12.2.1     OVERVIEW
      • 12.2.2     FINANCIALS
      • 12.2.3     PRODUCT PORTFOLIO
      • 12.2.4     KEY DEVELOPMENTS
      • 12.2.5     BUSINESS STRATEGY
      • 12.2.6     SWOT ANALYSIS
    • 12.3     CARDINAL HEALTH INC.
      • 12.3.1     OVERVIEW
      • 12.3.2     FINANCIALS
      • 12.3.3     PRODUCT PORTFOLIO
      • 12.3.4     KEY DEVELOPMENTS
      • 12.3.5     BUSINESS STRATEGY
      • 12.3.6     SWOT ANALYSIS
    • 12.4     CURIUM PHARMA
      • 12.4.1     OVERVIEW
      • 12.4.2     FINANCIALS
      • 12.4.3     PRODUCT PORTFOLIO
      • 12.4.4     KEY DEVELOPMENTS
      • 12.4.5     BUSINESS STRATEGY
      • 12.4.6     SWOT ANALYSIS
    • 12.5     FUJIFILM HOLDINGS CORPORATION
      • 12.5.1     OVERVIEW
      • 12.5.2     FINANCIALS
      • 12.5.3     PRODUCT PORTFOLIO
      • 12.5.4     KEY DEVELOPMENTS
      • 12.5.5     BUSINESS STRATEGY
      • 12.5.6     SWOT ANALYSIS
    • 12.6     GE COMPANY (GE HEALTHCARE)
      • 12.6.1     OVERVIEW
      • 12.6.2     FINANCIALS
      • 12.6.3     PRODUCT PORTFOLIO
      • 12.6.4     KEY DEVELOPMENTS
      • 12.6.5     BUSINESS STRATEGY
      • 12.6.6     SWOT ANALYSIS
    • 12.7     GUERBET
      • 12.7.1     OVERVIEW
      • 12.7.2     FINANCIALS
      • 12.7.3     PRODUCT PORTFOLIO
      • 12.7.4     KEY DEVELOPMENTS
      • 12.7.5     BUSINESS STRATEGY
      • 12.7.6     SWOT ANALYSIS
    • 12.8     LANTHEUS MEDICAL IMAGING INC.
      • 12.8.1     OVERVIEW
      • 12.8.2     FINANCIALS
      • 12.8.3     PRODUCT PORTFOLIO
      • 12.8.4     KEY DEVELOPMENTS
      • 12.8.5     BUSINESS STRATEGY
      • 12.8.6     SWOT ANALYSIS
    • 12.9     NOVARTIS INTERNATIONAL AG
      • 12.9.1     OVERVIEW
      • 12.9.2     FINANCIALS
      • 12.9.3     PRODUCT PORTFOLIO
      • 12.9.4     KEY DEVELOPMENTS
      • 12.9.5     BUSINESS STRATEGY
      • 12.9.6     SWOT ANALYSIS
    • 12.10     SUMITOMO CHEMICALS
      • 12.10.1     OVERVIEW
      • 12.10.2     FINANCIALS
      • 12.10.3     PRODUCT PORTFOLIO
      • 12.10.4     KEY DEVELOPMENTS
      • 12.10.5     BUSINESS STRATEGY
      • 12.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 2     MEDICAL IMAGING AGENTS CLINICAL TRIALS
      • TABLE 3     TECHNETIUM (TC-99M) CURRENT IRRADIATORS
      • TABLE 4     TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
      • TABLE 5     TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
      • TABLE 6     TECHNETIUM (TC-99M) CURRENT PROCESSORS
      • TABLE 7     POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
      • TABLE 8     FDA APPROVED DIAGNOSTIC RADIOPHARMACEUTICALS
      • TABLE 9     X-RAY/ CT CONTRAST AGENT MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
      • TABLE 10     X-RAY/ CT CONTRAST AGENT GLOBAL CONSUMPTION, (2020-2028) (MN L)
      • TABLE 11     MRI CONTRAST AGENT CONTRAST MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
      • TABLE 12     MRI CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (MN L)
      • TABLE 13     ULTRASOUND CONTRAST AGENTS MEDIATED PROCEDURE VOLUME, (2020-2028) (MN)
      • TABLE 14     ULTRASOUND CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (L)
      • TABLE 15     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
      • TABLE 16     CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 17     CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
      • TABLE 18     IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 19     IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 20     IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 21     IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 22     NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 23     NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 24     NON-IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 25     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 26     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 27     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 28     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 29     MACROCYCLIC IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 30     MACROCYCLIC NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 31     LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 32     LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 33     LINEAR IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 34     LINEAR NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 35     MICROBUBBLE CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 36     OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 37     NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 38     NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
      • TABLE 39     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 40     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 41     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 42     IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 43     XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 44     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 45     FLUORODEOXYGLUCOSE(18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 46     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 47     GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
      • TABLE 48     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 49     STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
      • TABLE 50     OTHER ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 51     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
      • TABLE 52     X-RAY/CT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 53     MRI MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 54     ULTRASOUND MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 55     SPECT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 56     PET MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 57     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 58     CARDIOVASCULAR APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 59     CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 60     GASTROINTESTINAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 61     MUSCULOSKELETAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 62     NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 63     NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 64     OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 65     PULMONARY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 66     HEPATOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 67     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 68     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
      • TABLE 69     INTRAVASCULAR ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 70     ORAL ROUTE OF ADMINISTATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 71     RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 72     OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 73     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
      • TABLE 74     DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 75     INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 76     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 77     HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 78     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 79     OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 80     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
      • TABLE 81     NORTH AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
      • TABLE 82     NORTH-AMERICA CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
      • TABLE 83     NORTH-AMERICA IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 84     NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE,(2020-2028) ($MN)
      • TABLE 85     NORTH-AMERICA GADOLINIUM CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 86     NORTH-AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 87     NORTH-AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 88     NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
      • TABLE 89     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
      • TABLE 90     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 91     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
      • TABLE 92     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
      • TABLE 93     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 94     NORTH AMERICA SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
      • TABLE 95     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
      • TABLE 96     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
      • TABLE 97     EUROPE CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
      • TABLE 98     EUROPE IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 99     EUROPE NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 100     EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 101     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 102     EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 103     EUROPE NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
      • TABLE 104     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
      • TABLE 105     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 106     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
      • TABLE 107     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
      • TABLE 108     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER,(2020-2028) ($MN)
      • TABLE 109     EUROPE SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
      • TABLE 110     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
      • TABLE 111     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
      • TABLE 112     APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
      • TABLE 113     APAC IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY,(2020-2028) ($MN)
      • TABLE 114     APAC NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 115     APAC GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 116     APAC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 117     APAC LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 118     APAC NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
      • TABLE 119     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
      • TABLE 120     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 121     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
      • TABLE 122     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
      • TABLE 123     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 124     ASIA-PACIFIC SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
      • TABLE 125     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
      • TABLE 126     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
      • TABLE 127     ROW CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
      • TABLE 128     ROW IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 129     ROW NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 130     ROW GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
      • TABLE 131     ROW MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 132     ROW LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
      • TABLE 133     ROW NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
      • TABLE 134     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
      • TABLE 135     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
      • TABLE 136     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
      • TABLE 137     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
      • TABLE 138     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
      • TABLE 139     ROW SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
      • TABLE 140     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
      • TABLE 141     APPROVALS (2020-2021)
      • TABLE 142     ACQUISITIONS, (2020-2021)
      • TABLE 143     AGREEMENTS, (2020-2021)
      • TABLE 144     PARTNERSHIPS, (2020-2021)
      • TABLE 145     EXPANSION, (2020-2021)
      • TABLE 146     OTHERS, (2020-2021)
      • TABLE 147     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
      • TABLE 148     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 149     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
      • TABLE 150     CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q1) ($MN)
      • TABLE 151     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2020 -2022) (Q1) ($MN)
      • TABLE 152     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 153     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
      • TABLE 154     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
      • TABLE 155     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
      • TABLE 156     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021) (Q3) ($MN)
      • TABLE 157     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 158     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q3) ($MN)
      • TABLE 159     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
      • TABLE 160     GUERBET TOTAL REVENUE, BY SEGMENT (2019-2021) (Q2) ($MN)
      • TABLE 161     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
      • TABLE 162     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
      • TABLE 163     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)
      • TABLE 164     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
      • TABLE 165     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
      • TABLE 166     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
      • TABLE 167     SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
      • TABLE 168     SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
      • TABLE 169     SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION, (2020-2028) ($MN) (2021)(%)
      • FIGURE 2     RESEARCH METHODOLOGY: MEDICAL IMAGING AGENTS GLOBAL MARKET
      • FIGURE 3     MEDICAL IMAGING AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     MEDICAL IMAGING AGENTS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     CONTRAST AGENTS CLINICAL TRIALS BASED ON PHASES
      • FIGURE 9     CONTRAST AGENTS CLINICAL TRIALS BASED ON APPLICATION
      • FIGURE 10     NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON PHASE
      • FIGURE 11     NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON APPLICATION
      • FIGURE 12     MEDICAL IMAGING AGENTS CLINICAL TRIALS BASED ON MODALITY
      • FIGURE 13     TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
      • FIGURE 14     CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 15     MEDICAL IMAGING AGENTS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 16     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 17     MRI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 18     X-RAY/CT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 19     ULTRASOUND AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 20     SPECT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 21     PET AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
      • FIGURE 22     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED X-RAY/CT PROCEDURE VOLUME (2021) (NO’S)
      • FIGURE 23     GLOBAL CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE (2021) ($MN)
      • FIGURE 24     NORTH AMERICA CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
      • FIGURE 25     EUROPE CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
      • FIGURE 26     ASIA – PACIFIC CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
      • FIGURE 27     ROW CT/ X-RAY PENETRATION, NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
      • FIGURE 28     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED MRI PROCEDURE VOLUME (2021) (NO’S)
      • FIGURE 29     GLOBAL MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
      • FIGURE 30     NORTH AMERICA MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
      • FIGURE 31     EUROPE MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED MARKET SIZE, (2021) ($MN)
      • FIGURE 32     ASIA – PACIFIC MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
      • FIGURE 33     ROW MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
      • FIGURE 34     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED ULTRASOUND IMAGING PROCEDURE VOLUME (2021) (NO’S)
      • FIGURE 35     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 36     CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 37     CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
      • FIGURE 38     IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 39     IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 40     IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 41     IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 42     NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 43     NON-IONIC MONOMER CONTRAST AGENTS MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 44     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 45     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 46     NUCLEAR IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 47     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 48     IODINE (I-123) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 49     IODINE (I-123) SUPPLY CHAIN
      • FIGURE 50     XENON (XE-133) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 51     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 52     FLUORINE-18 (F-18) SUPPLY CHAIN
      • FIGURE 53     SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
      • FIGURE 54     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
      • FIGURE 55     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON APPLICATION (2021) (%)
      • FIGURE 56     CARDIOVASCULAR APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 57     GASTROINTESTINAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 58     MUSCULOSKELETAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 59     NEPHROLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 60     OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 61     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
      • FIGURE 62     ORAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 63     RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 64     OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 65     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
      • FIGURE 66     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
      • FIGURE 67     HOSPITAL END-USER GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
      • FIGURE 68     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2020-2028) ($MN) & CAGR (%)
      • FIGURE 69     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 70     NORTH-AMERICA CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
      • FIGURE 71     NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 72     NORTH-AMERICA MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 73     NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 74     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
      • FIGURE 75     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
      • FIGURE 76     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
      • FIGURE 77     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
      • FIGURE 78     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
      • FIGURE 79     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 80     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 81     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 82     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 83     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 84     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
      • FIGURE 85     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 86     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 87     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 88     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 89     EUROPE MEDICAL CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
      • FIGURE 90     EUROPE IODINATED CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 91     EUROPE NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 92     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 93     EUROPE NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 94     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
      • FIGURE 95     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
      • FIGURE 96     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
      • FIGURE 97     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
      • FIGURE 98     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
      • FIGURE 99     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 100     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 101     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 102     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 103     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USER (2021 V/S 2028) ($MN)
      • FIGURE 104     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 105     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 106     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 107     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
      • FIGURE 108     ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
      • FIGURE 109     ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 110     ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 111     ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
      • FIGURE 112     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 113     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION(2021 V/S 2028) ($MN)
      • FIGURE 114     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 115     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 116     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 117     APAC CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
      • FIGURE 118     APAC NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 119     APAC MACROCYCLIC CONSTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 120     APAC NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 121     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
      • FIGURE 122     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
      • FIGURE 123     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
      • FIGURE 124     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
      • FIGURE 125     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
      • FIGURE 126     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 127     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
      • FIGURE 128     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 129     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 130     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
      • FIGURE 131     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
      • FIGURE 132     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION BY MOLECULE (2021 V/S 2028) ($MN)
      • FIGURE 133     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 134     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
      • FIGURE 135     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 136     SOUTH KOREA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 137     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 138     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
      • FIGURE 139     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 140     REST OF APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 141     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 142     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
      • FIGURE 143     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 144     ROW CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
      • FIGURE 145     ROW NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
      • FIGURE 146     ROW MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
      • FIGURE 147     ROW NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
      • FIGURE 148     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
      • FIGURE 149     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
      • FIGURE 150     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
      • FIGURE 151     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
      • FIGURE 152     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
      • FIGURE 153     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
      • FIGURE 154     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 155     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 156     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 157     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
      • FIGURE 158     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 159     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 160     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 161     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
      • FIGURE 162     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
      • FIGURE 163     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
      • FIGURE 164     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 165     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
      • FIGURE 166     KEY GROWTH STRATEGIES (2020–2021)
      • FIGURE 167     SWOT: BAYER GROUP
      • FIGURE 168     SWOT: BRACCO GROUP
      • FIGURE 169     SWOT: CARDINAL HEALTH, INC
      • FIGURE 170     SWOT: CURIUM PHARMA
      • FIGURE 171     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 172     SWOT: GE HEALTHCARE
      • FIGURE 173     SWOT: GUERBET
      • FIGURE 174     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 175     SWOT: NOVARTIS INTERNATIONAL AG
      • FIGURE 176     SWOT: SUMITOMO CHEMICALS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ADVANCED NUCLEAR IMAGING AGENTS INGREDIENTS
      • 2     ARRONAX
      • 3     ASCELIA PHARMA AB
      • 4     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION
      • 5     BAYER GROUP
      • 6     BEIJING BEILU PHARMACEUTICALS COMPANY LIMITED
      • 7     BEIJING ZHIBO BIOMEDICAL TECHNOLOGY CO. LTD.,
      • 8     BIEM PHARMACEUTICALS
      • 9     BLUE EARTH DIAGNOSTICS LIMITED
      • 10     BOARD OF RADIATION & ISOTOPE TECHNOLOGY
      • 11     BRACCO GROUP
      • 12     BTG INTERNATIONAL LTD
      • 13     BV CYCLOTRON VU
      • 14     CANADIAN ISOTOPE INNOVATIONS CORPORATION
      • 15     CARDINAL HEALTH INC.
      • 16     CELLECTAR BIOSCIENCES
      • 17     CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
      • 18     CHINA NATIONAL NUCLEAR CORPORATION (CHINA ISOTOPE & RADIATION CORPORATION)
      • 19     CURIUM PHARMA
      • 20     DIHAN PHARMA CO. LTD
      • 21     DONGKOOK LIFESCIENCE
      • 22     ECKERT & ZIEGLER STRAHLEN
      • 23     ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
      • 24     ELI LILLY & CO (AVID RADIOPHARMACEUTICALS)
      • 25     ESSENTIAL ISOTOPES
      • 26     EXEM FOAM INC
      • 27     FERRIC CONTRAST INC.
      • 28     FLUORO PHARMA
      • 29     FUJI PHARMA CO
      • 30     FUJIFILM HOLDING CORPORATION
      • 31     FUTURECHEM CO., LTD
      • 32     GALENICA SENESE S.R.L
      • 33     GE COMPANY (GE HEALTHCARE)
      • 34     GENUS MEDICAL TECHNOLOGIES
      • 35     GRATON PHARMA
      • 36     GUERBET
      • 37     HARMONY LIFE SCIENCES
      • 38     IMAX DIAGNOSTIC IMAGING LIMITED
      • 39     INSTITUTE OF ISOTOPES
      • 40     INTERNATIONAL ISOTOPES INC.
      • 41     IONETIX
      • 42     ISO ANALYTICAL LTD.
      • 43     ISORAD LTD
      • 44     ISO-TEX DIAGNOSTICS INC.
      • 45     ITHEMBA LABS
      • 46     ITM ISOTOPEN TECHNOLOGIEN MÜNCHEN AG
      • 47     J.B CHEMICALS AND PHARMACEUTICALS LTD
      • 48     JODAS EXPOIM PVT. LTD
      • 49     JSC ISOTOPE
      • 50     KREITCHMAN PET CTR
      • 51     LANTHEUS MEDICAL IMAGING INC
      • 52     LIFE MOLECULAR IMAGING GMBH
      • 53     MAGNUS HEALTH
      • 54     MAX DIAGNOSTIC IMAGING LIMITED
      • 55     MEDICAL ISOTOPES INC
      • 56     MOLECULAR THERANOSTICS LLC
      • 57     NANO-THERAPEUTICS
      • 58     NATIONAL NUCLEAR CORPORATION (CHINA ISOTOPE & RADIATION CORPORATION)
      • 59     NAVIDEA BIOPHARMACEUTICALS INC
      • 60     NCM USA BRONX LLC
      • 61     NORTHSTAR MEDICAL RADIOISOTOPES, LLC
      • 62     NOVARTIS INTERNATIONAL AG (ADVANCED ACCELERATOR APPLICATION)
      • 63     NUCLEAR RESEARCH AND CONSULTANCY GROUP
      • 64     NUKEMED INC.
      • 65     OTSUKA PHARMACEUTICAL CO., LTD
      • 66     PARS ISOTOPE CO
      • 67     PERMA-FIX MEDICAL SA
      • 68     PHARMALOGIC
      • 69     PRECISION NUCLEAR, LLC
      • 70     RADIOMEDIX
      • 71     REGE IMAGING & CINEFILMS PRIVATE LIMITED
      • 72     REVEAL PHARMACEUTICALS
      • 73     ROTOP PHARMAKA GMBH
      • 74     SAMYOUNG UNITECH
      • 75     SANOCHEMIA PHARMAZEUTIKA AG
      • 76     SHINE MEDICAL TECHNOLOGIES
      • 77     SIEMENS HEALTHINEERS GMBH
      • 78     SOFIE
      • 79     SOLCOM LIMITED
      • 80     SOTERA HEALTH LLC (NORDION INC) (U.S)
      • 81     SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NTP)
      • 82     SPAGO NANO MEDICALS
      • 83     SPINTECH MRI
      • 84     SUMITOMO CHEMICALS (NIHON MEDI PHYSICS CO LTD)
      • 85     SUN PHARMACEUTICAL INDUSTRIES LTD. (PHARMALUCENCE, INC.)
      • 86     SWAN ISOTOPEN AG
      • 87     TAEJOON PHARM CO. LTD.,
      • 88     THERAGNOSTICS LTD
      • 89     TRIVITRON HEALTHCARE
      • 90     UNIJULES LIFE SCIENCES LTD
      • 91     UNIMARK REMEDIES
      • 92     ZAG ZYKLOTRON AG
      • 93     ZHEJIANG STARRY PHARMA